estradiol-3-benzoate and Osteoporosis--Postmenopausal

estradiol-3-benzoate has been researched along with Osteoporosis--Postmenopausal* in 1 studies

Other Studies

1 other study(ies) available for estradiol-3-benzoate and Osteoporosis--Postmenopausal

Article	Year
Applying vibration in early postmenopausal osteoporosis promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells and suppresses postmenopausal osteoporosis progression. Bioscience reports, 2019, 09-30, Volume: 39, Issue:9 We aimed to evaluate whether applying low magnitude vibration (LMV) in early postmenopausal osteoporosis (PMO) suppresses its progression, and to investigate underlying mechanisms. Rats were randomly divided into Sham (Sham-operated), Sham+V, OVX (ovariectomized), OVX+E2 (estradiol benzoate), OVX+V (LMV at 12-20 weeks postoperatively), and OVX+Vi (LMV at 1-20 weeks postoperatively) groups. LMV was applied for 20 min once daily for 5 days weekly. V rats were loaded with LMV at 12-20 weeks postoperatively. Vi rats were loaded with LMV at 1-20 weeks postoperatively. Estradiol (E2) rats were intramuscularly injected at 12-20 weeks postoperatively once daily for 3 days. The bone mineral densities (BMDs), biomechanical properties, and histomorphological parameters of tibiae were analyzed. Topics: Animals; Bone Density; Bone Marrow Cells; Cell Differentiation; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation; Humans; Mesenchymal Stem Cells; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Tibia; Transcription Factors; Vibration	2019

Article

Year

Applying vibration in early postmenopausal osteoporosis promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells and suppresses postmenopausal osteoporosis progression.

Bioscience reports, 2019, 09-30, Volume: 39, Issue:9

We aimed to evaluate whether applying low magnitude vibration (LMV) in early postmenopausal osteoporosis (PMO) suppresses its progression, and to investigate underlying mechanisms. Rats were randomly divided into Sham (Sham-operated), Sham+V, OVX (ovariectomized), OVX+E2 (estradiol benzoate), OVX+V (LMV at 12-20 weeks postoperatively), and OVX+Vi (LMV at 1-20 weeks postoperatively) groups. LMV was applied for 20 min once daily for 5 days weekly. V rats were loaded with LMV at 12-20 weeks postoperatively. Vi rats were loaded with LMV at 1-20 weeks postoperatively. Estradiol (E2) rats were intramuscularly injected at 12-20 weeks postoperatively once daily for 3 days. The bone mineral densities (BMDs), biomechanical properties, and histomorphological parameters of tibiae were analyzed.

Topics: Animals; Bone Density; Bone Marrow Cells; Cell Differentiation; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation; Humans; Mesenchymal Stem Cells; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Tibia; Transcription Factors; Vibration

2019